192 related articles for article (PubMed ID: 33421017)
1. Fibroblast Growth Factor 9 Stimulates Neuronal Length Through NF-kB Signaling in Striatal Cell Huntington's Disease Models.
Yusuf IO; Chen HM; Cheng PH; Chang CY; Tsai SJ; Chuang JI; Wu CC; Huang BM; Sun HS; Chen CM; Yang SH
Mol Neurobiol; 2021 May; 58(5):2396-2406. PubMed ID: 33421017
[TBL] [Abstract][Full Text] [Related]
2. FGF9 induces neurite outgrowth upon ERK signaling in knock-in striatal Huntington's disease cells.
Yusuf IO; Chen HM; Cheng PH; Chang CY; Tsai SJ; Chuang JI; Wu CC; Huang BM; Sun HS; Chen CM; Yang SH
Life Sci; 2021 Feb; 267():118952. PubMed ID: 33383048
[TBL] [Abstract][Full Text] [Related]
3. Fibroblast Growth Factor 9 Suppresses Striatal Cell Death Dominantly Through ERK Signaling in Huntington's Disease.
Yusuf IO; Cheng PH; Chen HM; Chang YF; Chang CY; Yang HI; Lin CW; Tsai SJ; Chuang JI; Wu CC; Huang BM; Sun HS; Yang SH
Cell Physiol Biochem; 2018; 48(2):605-617. PubMed ID: 30021209
[TBL] [Abstract][Full Text] [Related]
4. Fibroblast growth factor 9 activates anti-oxidative functions of Nrf2 through ERK signalling in striatal cell models of Huntington's disease.
Yusuf IO; Chen HM; Cheng PH; Chang CY; Tsai SJ; Chuang JI; Wu CC; Huang BM; Sun HS; Yang SH
Free Radic Biol Med; 2019 Jan; 130():256-266. PubMed ID: 30391672
[TBL] [Abstract][Full Text] [Related]
5. Ginsenoside Rg1 exerts neuroprotective effects in 3-nitropronpionic acid-induced mouse model of Huntington's disease via suppressing MAPKs and NF-κB pathways in the striatum.
Yang X; Chu SF; Wang ZZ; Li FF; Yuan YH; Chen NH
Acta Pharmacol Sin; 2021 Sep; 42(9):1409-1421. PubMed ID: 33214696
[TBL] [Abstract][Full Text] [Related]
6. Mitigation of augmented extrasynaptic NMDAR signaling and apoptosis in cortico-striatal co-cultures from Huntington's disease mice.
Milnerwood AJ; Kaufman AM; Sepers MD; Gladding CM; Zhang L; Wang L; Fan J; Coquinco A; Qiao JY; Lee H; Wang YT; Cynader M; Raymond LA
Neurobiol Dis; 2012 Oct; 48(1):40-51. PubMed ID: 22668780
[TBL] [Abstract][Full Text] [Related]
7. Selective reduction of striatal mature BDNF without induction of proBDNF in the zQ175 mouse model of Huntington's disease.
Ma Q; Yang J; Li T; Milner TA; Hempstead BL
Neurobiol Dis; 2015 Oct; 82():466-477. PubMed ID: 26282324
[TBL] [Abstract][Full Text] [Related]
8. Gintonin, a ginseng-derived ingredient, as a novel therapeutic strategy for Huntington's disease: Activation of the Nrf2 pathway through lysophosphatidic acid receptors.
Jang M; Choi JH; Chang Y; Lee SJ; Nah SY; Cho IH
Brain Behav Immun; 2019 Aug; 80():146-162. PubMed ID: 30853569
[TBL] [Abstract][Full Text] [Related]
9. The cytokine and endocannabinoid systems are co-regulated by NF-κB p65/RelA in cell culture and transgenic mouse models of Huntington's disease and in striatal tissue from Huntington's disease patients.
Laprairie RB; Warford JR; Hutchings S; Robertson GS; Kelly ME; Denovan-Wright EM
J Neuroimmunol; 2014 Feb; 267(1-2):61-72. PubMed ID: 24360910
[TBL] [Abstract][Full Text] [Related]
10. Specific caspase interactions and amplification are involved in selective neuronal vulnerability in Huntington's disease.
Hermel E; Gafni J; Propp SS; Leavitt BR; Wellington CL; Young JE; Hackam AS; Logvinova AV; Peel AL; Chen SF; Hook V; Singaraja R; Krajewski S; Goldsmith PC; Ellerby HM; Hayden MR; Bredesen DE; Ellerby LM
Cell Death Differ; 2004 Apr; 11(4):424-38. PubMed ID: 14713958
[TBL] [Abstract][Full Text] [Related]
11. Endocannabinoid-Specific Impairment in Synaptic Plasticity in Striatum of Huntington's Disease Mouse Model.
Sepers MD; Smith-Dijak A; LeDue J; Kolodziejczyk K; Mackie K; Raymond LA
J Neurosci; 2018 Jan; 38(3):544-554. PubMed ID: 29192125
[TBL] [Abstract][Full Text] [Related]
12. Metabotropic glutamate receptor 5 positive allosteric modulators are neuroprotective in a mouse model of Huntington's disease.
Doria JG; Silva FR; de Souza JM; Vieira LB; Carvalho TG; Reis HJ; Pereira GS; Dobransky T; Ribeiro FM
Br J Pharmacol; 2013 Jun; 169(4):909-21. PubMed ID: 23489026
[TBL] [Abstract][Full Text] [Related]
13. Partial resistance to malonate-induced striatal cell death in transgenic mouse models of Huntington's disease is dependent on age and CAG repeat length.
Hansson O; Castilho RF; Korhonen L; Lindholm D; Bates GP; Brundin P
J Neurochem; 2001 Aug; 78(4):694-703. PubMed ID: 11520890
[TBL] [Abstract][Full Text] [Related]
14. NF-kB/NOS cross-talk induced by mitochondrial complex II inhibition: implications for Huntington's disease.
Napolitano M; Zei D; Centonze D; Palermo R; Bernardi G; Vacca A; Calabresi P; Gulino A
Neurosci Lett; 2008 Apr; 434(3):241-6. PubMed ID: 18329171
[TBL] [Abstract][Full Text] [Related]
15. The RAGE receptor and its ligands are highly expressed in astrocytes in a grade-dependant manner in the striatum and subependymal layer in Huntington's disease.
Kim J; Waldvogel HJ; Faull RL; Curtis MA; Nicholson LF
J Neurochem; 2015 Sep; 134(5):927-42. PubMed ID: 26011179
[TBL] [Abstract][Full Text] [Related]
16. Sulforaphane Ameliorates 3-Nitropropionic Acid-Induced Striatal Toxicity by Activating the Keap1-Nrf2-ARE Pathway and Inhibiting the MAPKs and NF-κB Pathways.
Jang M; Cho IH
Mol Neurobiol; 2016 May; 53(4):2619-35. PubMed ID: 26096705
[TBL] [Abstract][Full Text] [Related]
17. Neuroprotective role for the p50 subunit of NF-kappaB in an experimental model of Huntington's disease.
Yu Z; Zhou D; Cheng G; Mattson MP
J Mol Neurosci; 2000 Aug; 15(1):31-44. PubMed ID: 11211235
[TBL] [Abstract][Full Text] [Related]
18. Expression, pharmacology and functional activity of adenosine A1 receptors in genetic models of Huntington's disease.
Ferrante A; Martire A; Pepponi R; Varani K; Vincenzi F; Ferraro L; Beggiato S; Tebano MT; Popoli P
Neurobiol Dis; 2014 Nov; 71():193-204. PubMed ID: 25132555
[TBL] [Abstract][Full Text] [Related]
19. Full length mutant huntingtin is required for altered Ca2+ signaling and apoptosis of striatal neurons in the YAC mouse model of Huntington's disease.
Zhang H; Li Q; Graham RK; Slow E; Hayden MR; Bezprozvanny I
Neurobiol Dis; 2008 Jul; 31(1):80-8. PubMed ID: 18502655
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of BDNF and Full-Length TrkB Receptor Ameliorate Striatal Neural Survival in Huntington's Disease.
Silva A; Naia L; Dominguez A; Ribeiro M; Rodrigues J; Vieira OV; Lessmann V; Rego AC
Neurodegener Dis; 2015; 15(4):207-18. PubMed ID: 25896770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
